4
Changes in Ownership
C4 Therapeutics, Inc. Filed Acc 0001662579-25-000019
Chief Business Officer sold 1,159 shares at $3.15 ($3,651)
- Chief Business Officer gave up 4,103 shares (to pay taxes)
- Chief Business Officer acquired 56,500 shares (grant or award)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Boyle Scott N · Chief Business Officer
Table I: Non-derivative
5 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2025-02-13 | Shares withheld for taxes : show line 1 in the form 10b5-1 | −1,735 | $3.20 | $5,552 | 54,832 | D |
| 2025-02-14 | Grant or award : show line 2 in the form 10b5-1 | +56,500 | 111,332 | D | ||
| 2025-02-14 | Sale : show line 3 in the form 10b5-1 | −490 | $3.15 | $1,544 | 110,842 | D |
| 2025-02-14 | Shares withheld for taxes : show line 4 in the form 10b5-1 | −2,368 | $3.18 | $7,530 | 108,474 | D |
| 2025-02-18 | Sale : show line 5 in the form 10b5-1 | −669 | $3.15 | $2,107 | 107,805 | D |
| Open-market sales · 1,159 sh · avg $3.15 · $3,651 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2025-02-14 | Grant or award : show line 6 in the form 10b5-1 Stock Option (Right to Buy) | +84,700 | 84,700 | D |
Loading xslF345X05/wk-form4_1739915710.xml…